This study investigated the dose response relationship for the efficacy and safety of BAF312
compared to placebo in active DM patients over a treatment period of 6+6 months and to
determine the minimum dose required for a maximal clinical effect. The study was composed of
2 periods: a double-blind period 1 with BAF312 administered at different daily doses (0.5, 2,
10 mg and placebo) and a fixed-dose Period 2 in which BAF312 was administered at the dose of
2 mg daily .